Safety and efficacy of Mycoplasma gallisepticum TS-11 vaccine for the protection of layer pullets against challenge with virulent M. gallisepticum R-strain

Judit Bíró, J. Povazsán, L. Korösi, R. Glávits, L. Hufnagel, L. Stipkovits

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Mycoplasma gallisepticum TS-11 vaccine was studied for its safety and protective ability in 49-day-old M. gallisepticum-free and Mycoplasma synoviae-free commercial Tetra SL layer chickens. Sixty birds were distributed into four groups: 15 were unvaccinated but were challenged with M. gallisepticum R-strain, 15 were vaccinated by eye drop and then challenged with virulent M. gallisepticum R-strain 4 weeks post vaccination, 15 were designated as controls without vaccination and challenge, and 15 received TS-11 vaccine but no challenge. Based on the post-challenge clinical signs, body weight gain, gross pathological examination of air sacs and peritoneum, histological examination of the trachea, lung, spleen and liver, and reisolation of mycoplasmas from inner organs, the TS-11 vaccine is safe and does not produce clinical signs, a major decrease of body weight gain or pathological lesions. Vaccination induced a slight serological response to M. gallisepticum antigen in serum plate agglutination and blocking enzyme-linked immunosorbent assay tests and prevented development clinical signs of airsacculitis, peribronchitis and interstitial pneumonia on M. gallisepticum challenge.

Original languageEnglish
Pages (from-to)341-347
Number of pages7
JournalAvian Pathology
Volume34
Issue number4
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Mycoplasma gallisepticum
pullets
Vaccines
vaccines
Safety
Vaccination
vaccination
Weight Gain
Mycoplasma synoviae
weight gain
Body Weight
Air Sacs
peritoneum
trachea (vertebrates)
air sacs
body weight
Ophthalmic Solutions
Mycoplasma
Peritoneum
Interstitial Lung Diseases

ASJC Scopus subject areas

  • Immunology
  • veterinary(all)

Cite this

Safety and efficacy of Mycoplasma gallisepticum TS-11 vaccine for the protection of layer pullets against challenge with virulent M. gallisepticum R-strain. / Bíró, Judit; Povazsán, J.; Korösi, L.; Glávits, R.; Hufnagel, L.; Stipkovits, L.

In: Avian Pathology, Vol. 34, No. 4, 08.2005, p. 341-347.

Research output: Contribution to journalArticle

@article{afc3d26d4c5f4bf198118621f39332fb,
title = "Safety and efficacy of Mycoplasma gallisepticum TS-11 vaccine for the protection of layer pullets against challenge with virulent M. gallisepticum R-strain",
abstract = "Mycoplasma gallisepticum TS-11 vaccine was studied for its safety and protective ability in 49-day-old M. gallisepticum-free and Mycoplasma synoviae-free commercial Tetra SL layer chickens. Sixty birds were distributed into four groups: 15 were unvaccinated but were challenged with M. gallisepticum R-strain, 15 were vaccinated by eye drop and then challenged with virulent M. gallisepticum R-strain 4 weeks post vaccination, 15 were designated as controls without vaccination and challenge, and 15 received TS-11 vaccine but no challenge. Based on the post-challenge clinical signs, body weight gain, gross pathological examination of air sacs and peritoneum, histological examination of the trachea, lung, spleen and liver, and reisolation of mycoplasmas from inner organs, the TS-11 vaccine is safe and does not produce clinical signs, a major decrease of body weight gain or pathological lesions. Vaccination induced a slight serological response to M. gallisepticum antigen in serum plate agglutination and blocking enzyme-linked immunosorbent assay tests and prevented development clinical signs of airsacculitis, peribronchitis and interstitial pneumonia on M. gallisepticum challenge.",
author = "Judit B{\'i}r{\'o} and J. Povazs{\'a}n and L. Kor{\"o}si and R. Gl{\'a}vits and L. Hufnagel and L. Stipkovits",
year = "2005",
month = "8",
doi = "10.1080/03079450500179913",
language = "English",
volume = "34",
pages = "341--347",
journal = "Avian Pathology",
issn = "0307-9457",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy of Mycoplasma gallisepticum TS-11 vaccine for the protection of layer pullets against challenge with virulent M. gallisepticum R-strain

AU - Bíró, Judit

AU - Povazsán, J.

AU - Korösi, L.

AU - Glávits, R.

AU - Hufnagel, L.

AU - Stipkovits, L.

PY - 2005/8

Y1 - 2005/8

N2 - Mycoplasma gallisepticum TS-11 vaccine was studied for its safety and protective ability in 49-day-old M. gallisepticum-free and Mycoplasma synoviae-free commercial Tetra SL layer chickens. Sixty birds were distributed into four groups: 15 were unvaccinated but were challenged with M. gallisepticum R-strain, 15 were vaccinated by eye drop and then challenged with virulent M. gallisepticum R-strain 4 weeks post vaccination, 15 were designated as controls without vaccination and challenge, and 15 received TS-11 vaccine but no challenge. Based on the post-challenge clinical signs, body weight gain, gross pathological examination of air sacs and peritoneum, histological examination of the trachea, lung, spleen and liver, and reisolation of mycoplasmas from inner organs, the TS-11 vaccine is safe and does not produce clinical signs, a major decrease of body weight gain or pathological lesions. Vaccination induced a slight serological response to M. gallisepticum antigen in serum plate agglutination and blocking enzyme-linked immunosorbent assay tests and prevented development clinical signs of airsacculitis, peribronchitis and interstitial pneumonia on M. gallisepticum challenge.

AB - Mycoplasma gallisepticum TS-11 vaccine was studied for its safety and protective ability in 49-day-old M. gallisepticum-free and Mycoplasma synoviae-free commercial Tetra SL layer chickens. Sixty birds were distributed into four groups: 15 were unvaccinated but were challenged with M. gallisepticum R-strain, 15 were vaccinated by eye drop and then challenged with virulent M. gallisepticum R-strain 4 weeks post vaccination, 15 were designated as controls without vaccination and challenge, and 15 received TS-11 vaccine but no challenge. Based on the post-challenge clinical signs, body weight gain, gross pathological examination of air sacs and peritoneum, histological examination of the trachea, lung, spleen and liver, and reisolation of mycoplasmas from inner organs, the TS-11 vaccine is safe and does not produce clinical signs, a major decrease of body weight gain or pathological lesions. Vaccination induced a slight serological response to M. gallisepticum antigen in serum plate agglutination and blocking enzyme-linked immunosorbent assay tests and prevented development clinical signs of airsacculitis, peribronchitis and interstitial pneumonia on M. gallisepticum challenge.

UR - http://www.scopus.com/inward/record.url?scp=23744471629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744471629&partnerID=8YFLogxK

U2 - 10.1080/03079450500179913

DO - 10.1080/03079450500179913

M3 - Article

VL - 34

SP - 341

EP - 347

JO - Avian Pathology

JF - Avian Pathology

SN - 0307-9457

IS - 4

ER -